Company: HURA
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001193125-25-313799
Chunk: 59

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-12-10
Form: 424B5
Chunk 59
---
 for our agreement, set forth in a Warrant Amendment Agreement between us and each Deferral Investor (the “Warrant Amendment Agreements”), to extend the expiration dates of certain warrants to purchase an aggregate of 1.5 million shares of Common Stock that were issued by our predecessor in a 2024 private placement of convertible notes (the “2024 Warrants”). Under the Warrant Amendment Agreements, the expiration dates of the 2024 Warrants were extended to December 31, 2030. We currently plan to use the net proceeds from the Private Placement for cash requirements to fund expenses acquired in connection with the Kineta Merger, to fund the initiation of the Phase 3 Trial for IFx-2.0,to fund the advancement of TBS-2025to a Phase 2 trial and for other working capital needs. 26

The Private Placement Warrants have an exercise price per share equal to $3.3125 and will expire on December 3, 2030. The exercise price of the Private Placement Warrants is subject to proportional adjustment for stock splits, reverse stock splits, and similar transactions. The shares of Common Stock, Private Placement Warrants and the shares of Common Stock issuable upon exercise of the Private Placement Warrants were issued in the Private Placement and have not been registered under the Securities Act and are instead being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and/or Rule 506(b) promulgated thereunder. When we refer to “selling stockholders” in this prospectus, we mean persons listed in the table below, as well as such person’s transferees, pledgees or donees or its or their respective successors. The information regarding shares beneficially owned after the offering assumes the sale of all shares offered by the selling stockholders. The table below lists the selling stockholder and other information regarding the beneficial ownership (as determined under Section 13(d) of the Securities Exchange and the rules and regulations thereunder) of the shares of Common Stock held by the selling stockholder. The second column lists the number of shares of Common Stock beneficially owned by the selling stockholder as of November 3, 2025. The third column lists the shares of Common Stock being offered by this prospectus by the selling stockholder. The fourth column assumes the sale of all of the shares offered by the selling stockholder pursuant to this prospectus. The fifth column lists the percentage of Common Stock owned by the selling stockholder,